Lee, K., Mahalingam, D., Shim, B. Y., Kim, I., Oh, D., Uronis, H., Sym, S. J., Sonbol, M., Almhanna, K., Tejani, M. A., Kang, B., Kagey, M. H., Stilian, M., Jia, C., Sirard, C. A., Altura, R., Ajani, J. A., Klempner, S. J. (2026). Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B. Nature Communications. https://doi.org/10.1038/s41467-026-69394-0